Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00108225 · ClinicalTrials.gov registry record · NA

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

A NA study of Diabetes Mellitus, Type 2, sponsored by US Department of Veterans Affairs.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT00108225 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 8 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00108225, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

In this study we tested the hypothesis that an increase in protein content of the diet will result in an increase in the 24-hour integrated circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations and an increase in lean body mass in people with untreated type 2 diabetes.

Conditions Studied

Interventions

  • OTHER LoBag Diet - test phase
  • OTHER LoBAG Diet - control phase

Study Locations (1)

Minnesota

  • VA Medical Center, Minneapolis - Minneapolis

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2004-07
Est. Completion 2009-05
Phase NA

Sponsor

US Department of Veterans Affairs

632 total trials

What the Registry Record Tells You About NCT00108225

The ClinicalTrials.gov registry entry for NCT00108225 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which LoBag Diet - test phase is the first listed.

NCT00108225 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00108225 about?

NCT00108225 is a clinical study titled "Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)". In this study we tested the hypothesis that an increase in protein content of the diet will result in an increase in the 24-hour integrated circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations and an increase in lean body mass in people with untreated type 2 diabet...

What is the current status of trial NCT00108225?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2004-07. Estimated completion is 2009-05.

What conditions does trial NCT00108225 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00108225?

The interventions under investigation include: LoBag Diet - test phase (OTHER), LoBAG Diet - control phase (OTHER).

Who is sponsoring clinical trial NCT00108225?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00108225 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.